Sortilin As A Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia

Background: the overexpression of sortilin/neurotensin receptor 3 has previously been reported in various human solid tumors but not in hematological malignancies. here, we report the overexpression of sortilin in leukemic cells from patients with chronic lymphocytic leukemia (cll). methods: flow cytometry was used to compare the expression of sortilin in cll patients (n=52) and healthy individuals (n=26). also, in vitro apoptosis induction was assessed in cll peripheral blood mononuclear cell (pbmcs) following directly targeting of sortilin. results: the results showed a significant expression of sortilin on the surface of cll pbmcs (range from 2.2 to 71.5%) in comparison to healthy individuals (range from 0.03 to 7.4%) (p≤0.0001). the optimal cut-off value of sortilin expression was determined at 7.2% with high sensitivity and specificity. treatment of leukemic cells with anti-sortilin antibody could induce apoptosis without any effect on normal cells. conclusion: apoptosis induction in cll cells together with a significant correlation between the expression of sortilin and cd23 represent a possible functional role of sortilin in leukemogenesis of cll cells. therefore, sortilin might be considered as a promising novel biomarker in diagnosis, monitoring, and therapy of patients with cll.